Nanjing Vazyme Biotech Co Ltd (688105) - Total Liabilities
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has total liabilities worth CN¥1.31 Billion CNY (≈ $191.43 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nanjing Vazyme Biotech Co Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 688105 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Nanjing Vazyme Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Colorlight Cloud Tech Ltd. A
SHE:301391
|
China | CN¥478.54 Million |
|
Lotte Tour Dev
KO:032350
|
Korea | ₩1.80 Trillion |
|
Giant Manufacturing Co Ltd
TW:9921
|
Taiwan | NT$33.80 Billion |
|
Imperial Metals Corporation
TO:III
|
Canada | CA$878.77 Million |
|
KSB SE & Co. KGaA
XETRA:KSB
|
Germany | €1.55 Billion |
|
Hangzhou Sunrise Technology Co Ltd
SHE:300360
|
China | CN¥719.08 Million |
|
Central Pacific Financial Corp
NYSE:CPF
|
USA | $6.82 Billion |
|
Tianjin Benefo Tejing Electric Co Ltd
SHG:600468
|
China | CN¥1.77 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Nanjing Vazyme Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Nanjing Vazyme Biotech Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanjing Vazyme Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanjing Vazyme Biotech Co Ltd (2017–2025)
The table below shows the annual total liabilities of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.24 Billion ≈ $180.97 Million |
+11.92% |
| 2024-12-31 | CN¥1.11 Billion ≈ $161.70 Million |
-35.64% |
| 2023-12-31 | CN¥1.72 Billion ≈ $251.24 Million |
+23.24% |
| 2022-12-31 | CN¥1.39 Billion ≈ $203.85 Million |
+190.33% |
| 2021-12-31 | CN¥479.83 Million ≈ $70.21 Million |
+71.81% |
| 2020-12-31 | CN¥279.28 Million ≈ $40.87 Million |
+124.65% |
| 2019-12-31 | CN¥124.31 Million ≈ $18.19 Million |
+46.82% |
| 2018-12-31 | CN¥84.67 Million ≈ $12.39 Million |
+125.34% |
| 2017-12-31 | CN¥37.57 Million ≈ $5.50 Million |
-- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more